Albireo Pharma, Inc.
ALBO · NASDAQ
9/30/2022 | 6/30/2022 | 3/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.23 | 0.33 | -0.01 | 0.09 |
| FCF Yield | -7.80% | -9.53% | -6.17% | -3.15% |
| EV / EBITDA | -4.56 | -5.88 | -9.42 | 25.03 |
| Quality | ||||
| ROIC | -12.43% | -20.33% | -18.38% | -3.33% |
| Gross Margin | 93.78% | 90.54% | 96.57% | 97.16% |
| Cash Conversion Ratio | 0.78 | 0.91 | 0.83 | 1.27 |
| Growth | ||||
| Revenue 3-Year CAGR | 68.37% | 65.61% | 62.38% | 61.49% |
| Free Cash Flow Growth | 19.98% | -4.02% | -151.55% | 48.79% |
| Safety | ||||
| Net Debt / EBITDA | 6.42 | 4.60 | 5.24 | -28.22 |
| Interest Coverage | -13.70 | -13.55 | -13.75 | -3.53 |
| Efficiency | ||||
| Inventory Turnover | 0.19 | 0.37 | 0.13 | 4.77 |
| Cash Conversion Cycle | -540.40 | -362.22 | -1,732.43 | -606.06 |